Artelo Capital Expenditures vs End Period Cash Flow Analysis
| ARTL Stock | USD 1.03 0.07 6.36% |
Artelo Biosciences financial indicator trend analysis is way more than just evaluating Artelo Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Artelo Biosciences is a good investment. Please check the relationship between Artelo Biosciences Capital Expenditures and its End Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.
Capital Expenditures vs End Period Cash Flow
Capital Expenditures vs End Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Artelo Biosciences Capital Expenditures account and End Period Cash Flow. At this time, the significance of the direction appears to have very week relationship.
The correlation between Artelo Biosciences' Capital Expenditures and End Period Cash Flow is 0.25. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Artelo Biosciences, assuming nothing else is changed. The correlation between historical values of Artelo Biosciences' Capital Expenditures and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Artelo Biosciences are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Capital Expenditures i.e., Artelo Biosciences' Capital Expenditures and End Period Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.25 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Capital Expenditures
Capital Expenditures are funds used by Artelo Biosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Artelo Biosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.End Period Cash Flow
Most indicators from Artelo Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Artelo Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.The value of Selling General Administrative is expected to slide to about 2.3 M. The value of Issuance Of Capital Stock is estimated to slide to about 538.6 K
Artelo Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Artelo Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Artelo Biosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 6.5M | 4.4M | 12.6M | 20.4M | 13.0M | 13.7M | |
| Total Stockholder Equity | 5.5M | 3.9M | 12.0M | 19.4M | 11.8M | 12.3M | |
| Net Tangible Assets | (135.0K) | 3.4M | 1.8M | 10.0M | 11.5M | 12.1M | |
| Net Debt | (4.4M) | (2.1M) | (6.5M) | (6.8M) | (6.1M) | (5.8M) | |
| Retained Earnings | (4.8M) | (9.5M) | (16.9M) | (31.0M) | (40.3M) | (38.3M) | |
| Cash | 4.4M | 2.1M | 6.6M | 6.9M | 2.8M | 2.6M | |
| Cash And Short Term Investments | 4.4M | 2.1M | 10.1M | 17.5M | 20.2M | 21.2M | |
| Common Stock Total Equity | 11.3K | 14.0K | 3.4K | 5.0K | 4.5K | 6.3K | |
| Common Stock Shares Outstanding | 144.8K | 247.2K | 1.2M | 2.8M | 3.2M | 3.3M | |
| Liabilities And Stockholders Equity | 6.5M | 4.4M | 12.6M | 20.4M | 23.5M | 24.7M | |
| Other Stockholder Equity | 10.3M | 13.3M | 28.9M | 50.7M | 58.3M | 61.2M | |
| Total Liab | 1.0M | 502.2K | 593K | 1.0M | 1.3M | 1.4M | |
| Total Current Assets | 4.4M | 2.3M | 10.3M | 18.3M | 11.0M | 11.5M | |
| Common Stock | 3.4K | 5.0K | 25K | 3K | 3.5K | 3.3K | |
| Other Current Liab | 323.8K | (478.3K) | (488K) | (852K) | (766.8K) | (728.5K) | |
| Total Current Liabilities | 1.0M | 502.2K | 526K | 998K | 1.3M | 1.4M | |
| Accounts Payable | 348.9K | 490.2K | 493K | 905K | 1.2M | 1.3M | |
| Other Current Assets | 18.6K | 195.1K | 252K | 789K | 554K | 581.7K | |
| Accumulated Other Comprehensive Income | (9.8K) | 63.8K | 18K | (254K) | (228.6K) | (217.2K) | |
| Property Plant Equipment | 563.0 | 721.0 | 246.0 | 90K | 103.5K | 108.7K | |
| Non Current Assets Total | 2.0M | 2.0M | 2.3M | 2.1M | 2.1M | 1.5M | |
| Non Currrent Assets Other | 563.0 | 2.0M | 189K | 3K | 3.5K | 3.3K | |
| Non Current Liabilities Total | 529.3K | 348.9K | 490.2K | 67K | 23K | 0.0 | |
| Net Invested Capital | 5.5M | 3.9M | 12.0M | 11.8M | 13.5M | 7.1M | |
| Net Working Capital | 3.4M | 1.8M | 9.8M | 9.7M | 11.1M | 11.7M | |
| Property Plant And Equipment Net | 721.0 | 246.0 | 90K | 60K | 21K | 31.6K | |
| Property Plant And Equipment Gross | 721.0 | 246.0 | 90K | 21K | 24.2K | 24.5K | |
| Capital Stock | 3.4K | 5.0K | 25K | 3K | 2.7K | 2.6K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Return On Assets (0.54) | Return On Equity (0.89) |
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.